Immuron Posts 6% FY26 Sales Rise Led by Canada and US Growth

Global Sales Growth Sustains Momentum

Immuron Limited (ASX:IMC, NASDAQ: IMRN) has delivered a 6% increase in unaudited FY26 sales, reaching AUD 7.7 million, marking four consecutive quarters of growth compared to the prior year. The company’s flagship product Travelan®, an over-the-counter immune supplement targeting gastrointestinal pathogens, continues to gain traction globally.

Global sales accounted for AUD 5.8 million, up 10% year-on-year, with the second half of FY26 contributing AUD 2.5 million, a 6% increase. Notably, the Canadian market showed remarkable strength, with FY26 sales of AUD 1.8 million (USD 1.2 million), reflecting a 7% rise on the prior year. Q4 sales in Canada alone surged 427%, driven by expanded retail listings and consumer promotions.

Australian Sales Show Mixed Signals Amid Marketing Push

Australia’s FY26 sales were down 55% to AUD 0.2 million, a stark contrast to the global trend. However, the second half of the year saw a dramatic turnaround with sales up over 1000% and Q4 sales rising 376% year-on-year. This rebound is attributed to extensive digital and social media marketing, increased in-store promotions, new store listings secured in FY25, and a boost from increased South East Asian travel. The launch of new Travelan packaging and creative in Q4 is expected to further support sales momentum.

US Market Growth Tempered by Currency Strength

In the US, sales in AUD terms were slightly down by 1% in the second half of FY26 to AUD 0.9 million, though USD sales rose 9% to USD 0.6 million over the same period. The discrepancy reflects the impact of a stronger Australian dollar against the US dollar. Marketing initiatives including an enhanced Amazon store presence, dedicated US social media pages, and increased paid and organic social media campaigns have contributed to the underlying growth in the US market.

Pipeline Products and Future Prospects

Beyond Travelan, Immuron is advancing its product pipeline with IMM-529, targeting Clostridioides difficile infection, and ProIBS®, a medical device for irritable bowel syndrome symptoms distributed exclusively in Australia and New Zealand. IMM-529 has shown promising preclinical results and has secured FDA approval for a Phase 2 trial commencing in 2026, aiming to address a significant unmet need in infectious disease treatment.

Immuron’s proprietary platform technology leverages hyper-immune bovine colostrum antibodies, enabling orally active therapies that target a range of enteric pathogens. Travelan’s mechanism involves binding to diarrhea-causing bacteria to prevent colonization, a critical advantage in managing travelers’ diarrhea, a common affliction among international travellers and deployed military personnel.

While the unaudited sales figures reflect positive growth, currency fluctuations and regional market dynamics inject some uncertainty into the near-term outlook. The company’s ongoing marketing investments and product development efforts will be key to sustaining growth trajectories across its core markets.